Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-h6jzd Total loading time: 0.001 Render date: 2025-02-23T06:17:15.921Z Has data issue: false hasContentIssue false

Botulinum Toxin

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Botulinum toxins are potent neurotoxins produced by Clostridium botulinum. Two of the seven available biological serotypes of botulinum toxin are used in clinical practice, those being serotypes A and B. They are proteins comprising a heavy chain and a light chain. The two chains link via a disulphide bond.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 57 - 69
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Chinnapongse, R, Gullo, K, Nemeth, P, Zhang, Y, Griggs, L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson’s disease: a prospective double-blind trial. Mov Disord 2012; 27(2): 219–226.CrossRefGoogle ScholarPubMed
Isaacson, SH, Ondo, W, Jackson, CE, Trosch, RM, Molho, E, Pagan, F, Lew, M, Dashtipour, K, Clinch, T, Espay, AJ. Safety and efficacy of rimabotulinumtoxinB for treatment of sialorrhea in adults: a randomized clinical trial. JAMA Neurol 2020; 77(4): 461–469.CrossRefGoogle ScholarPubMed
Jost, WH. Use of botulinum neurotoxin in Parkinson’s disease: a critical appraisal. Toxins (Basel) 2021; 13(2): 87.CrossRefGoogle ScholarPubMed
Jost, WH, Friedman, A, Michel, O, Oehlwein, C, Slawek, J, Bogucki, A, Ochudlo, S, Banach, M, Pagan, F, Flatau-Baqué, B, Csikós, J, Cairney, CJ, Blitzer, A. SIAXI: placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology 2019; 92(17): e1982–e1991.CrossRefGoogle ScholarPubMed
Ondo, WG, Hunter, C, Moore, W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology 2004; 62(1): 37–40.CrossRefGoogle ScholarPubMed

References

Abusrair, AH, Elsekaily, W, Bohlega, S. Tremor in Parkinson’s disease: from pathophysiology to advanced therapies. Tremor Other Hyperkinet Mov (N Y) 2022; 12: 29.CrossRefGoogle ScholarPubMed
AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 22 December 2022 via www.medicinescomplete.com.Google Scholar
Botulinum toxin. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 22 December 2022 via www.medicinescomplete.com.Google Scholar
Hajebrahimi, S, Chapple, CR, Pashazadeh, F, Salehi-Pourmehr, H. Management of neurogenic bladder in patients with Parkinson’s disease: a systematic review. Neurourol Urodyn 2019; 38(1): 31–62.CrossRefGoogle ScholarPubMed
Huang, P, Li, YY, Park, JE, Huang, P, Xiao, Q, Wang, Y, Chen, S, Chen, SD, Liu, J, Wu, YW. Effects of onabotulinum toxin A on gait in Parkinson’s disease patients with foot dystonia. Can J Neurol Sci 2022; 49(1): 123–128.CrossRefGoogle ScholarPubMed
Isaacson, J, Patel, S, Torres-Yaghi, Y, Pagán, F. Sialorrhea in Parkinson’s disease. Toxins (Basel) 2020; 12(11): 691.CrossRefGoogle ScholarPubMed
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 22 December 2022 via www.medicinescomplete.com.Google Scholar
Jost, WH, Friedman, A, Michel, O, Oehlwein, C, Slawek, J, Bogucki, A, Ochudlo, S, Banach, M, Pagan, F, Flatau-Baqué, B, Dorsch, U, Csikós, J, Blitzer, A. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks. Parkinsonism Relat Disord 2020; 70: 23–30.CrossRefGoogle ScholarPubMed
Knüpfer, SC, Schneider, SA, Averhoff, MM, Naumann, CM, Deuschl, G, Jünemann, KP, Hamann, MF. Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson’s disease. BMC Urol 2016; 16(1): 55.CrossRefGoogle Scholar
Lagalla, G, Millevolte, M, Capecci, M, Provinciali, L, Ceravolo, MG. Long-lasting benefits of botulinum toxin type B in Parkinson’s disease-related drooling. J Neurol 2009; 256(4): 563–567.CrossRefGoogle Scholar
Mittal, SO, Machado, D, Richardson, D, Dubey, D, Jabbari, B. Botulinum toxin in Parkinson disease tremor: a randomized, double-blind, placebo-controlled study with a customized injection approach. Mayo Clin Proc 2017; 92(9): 1359–1367.CrossRefGoogle ScholarPubMed
Rukavina, K, Leta, V, Sportelli, C, Buhidma, Y, Duty, S, Malcangio, M, Ray Chaudhuri, K. Pain in Parkinson’s disease: new concepts in pathogenesis and treatment. Curr Opin Neurol 2019; 32(4): 579–588.CrossRefGoogle ScholarPubMed
Samotus, O, Lee, J, Jog, M. Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. PLoS One 2017; 12(6): e0178670.CrossRefGoogle ScholarPubMed
Samotus, O, Mahdi, Y, Jog, M. Real-world longitudinal experience of botulinum toxin therapy for Parkinson and essential tremor. Toxins (Basel) 2022; 14(8): 557.CrossRefGoogle Scholar
Shabir, H, Hashemi, S, Al-Rufayie, M, Adelowo, T, Riaz, U, Ullah, U, Alam, B, Anwar, M, de Preux, L. Cost–utility analysis of oxybutynin vs. onabotulinumtoxinA (Botox) in the treatment of overactive bladder syndrome. Int J Environ Res Public Health 2021; 18(16): 8743.CrossRefGoogle ScholarPubMed
Tassorelli, C, De Icco, R, Alfonsi, E, Bartolo, M, Serrao, M, Avenali, M, De Paoli, I, Conte, C, Pozzi, NG, Bramanti, P, Nappi, G, Sandrini, G. Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study. Parkinsonism Relat Disord 2014; 20(11): 1140–1144.CrossRefGoogle ScholarPubMed
Vurture, G, Peyronnet, B, Feigin, A, Biagioni, MC, Gilbert, R, Rosenblum, N, Frucht, S, Di Rocco, A, Nitti, VW, Brucker, BM. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson’s disease. Neurourol Urodyn 2018; 37(8): 2669–2677.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Botulinum Toxin
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.008
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Botulinum Toxin
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.008
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Botulinum Toxin
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.008
Available formats
×